[Skip to Content]
[Skip to Content Landing]
Medical News & Perspectives
February 28, 2001

Former Addicts Face Barriers to Treatment for HCV

Author Affiliations

Not Available

Not Available

JAMA. 2001;285(8):1003-1005. doi:10.1001/jama.285.8.1003

Most injection drug users, including those who succeed in kicking the habit, are left with a worrisome legacy: infection with hepatitis C virus (HCV). But for a variety of reasons, some former addicts who develop HCV-related liver disease—notably those receiving methadone maintenance therapy (MMT)—are confronted with barriers to getting much-needed treatment for their illness, barriers that sometimes force them to choose between dying of liver disease and risking relapse and a return to abusing drugs.

First Page Preview View Large
First page PDF preview
First page PDF preview